Rozlytrek (entrectinib) — Medica
Solid tumors (NTRK gene fusion-positive)
Initial criteria
- age ≥ 1 month
- tumor is positive for NTRK gene fusion
- tumor is metastatic OR surgical resection of tumor will likely result in severe morbidity
Approval duration
1 year